Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04996160Phase 1Completed
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palbociclib in acute lymphoblastic leukemia (ALL) (2 cohorts). Primary endpoint: Dose-limiting Toxicity at 30 days. Started Jul 2021; status: completed.
02
Drugs
palbociclib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04996160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996160.